Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERTO: Cobimetinib in CMML With RAS Pathway Mutations
NCT04409639Phase 2Active, not recruiting
- Sponsor
- University of Utah
- Start
- Jan 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cobimetinib in chronic myelomonocytic leukemia (CMML), sponsored by University of Utah. Started Jan 2021; status: active, not recruiting.
02
Drugs
cobimetinib
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04409639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409639.